GCS 100 IV - La Jolla Pharma
La Jolla: Corporate Presentation (La Jolla) - Mar 14, 2015 - “Additional Confirmatory Data From Extension Study”; “Statistically Significant Change in eGFR at 16 Weeks vs. 30 mg/m2 Group and Placebo” 
P2a data • Chronic Kidney Disease • Renal Disease
http://lajollapharmaceutical.com/wp-content/uploads/2015/02/Feb-2015-Corporate-Presentation.pdf
 
Mar 14, 2015
 
.
 
a81b2717-839f-42af-973a-d5412cd192d0.png